A Case of Transfusion Independence in a Patient with Myelodysplastic Syndrome Using Deferasirox, Sustained for Two Years after Stopping Therapy

Abstract

Patients with myelodysplastic syndrome (mds) experience clinical complications related to progressive marrow failure and have an increased risk of developing acute myeloid leukemia. Frequent red blood cell transfusion can lead to clinical iron overload and is associated with decreased survival in mds patients. Iron chelation therapy reduces markers of iron overload and prevents end-organ damage.Here, we present the case of a patient with lowrisk mds with transfusional iron overload. He was treated for 2 years with an oral iron chelator, deferasirox, and after 12 months of treatment, he experienced a hemoglobin increase of more than 50 g/L, becoming transfusion-independent. He has remained transfusion-independent, with a normal hemoglobin level, for more than 2 years since stopping chelation therapy. Hematologic and erythroid responses have previously been reported in mds patients treated with iron chelation. The durability of our patient’sresponse suggests that iron chelation might alter the natural history of mds in some patients.

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations

“… 32 Similarly, the same finding has also been seen in MDS patients after starting deferasirox. 33 , 34 The significance of this management modality needs to be addressed in future studies.…”